Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2008 1
2009 4
2010 6
2011 7
2012 6
2013 15
2014 13
2015 18
2016 10
2017 11
2018 15
2019 11
2020 14
2021 14
2022 7
2023 11
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Stool Glycoproteomics Signatures of Pre-Cancerous Lesions and Colorectal Cancer.
Soares J, Eiras M, Ferreira D, Santos DAR, Relvas-Santos M, Santos B, Gonçalves M, Ferreira E, Vieira R, Afonso LP, Santos LL, Dinis-Ribeiro M, Lima L, Ferreira JA. Soares J, et al. Among authors: santos ll. Int J Mol Sci. 2024 Mar 27;25(7):3722. doi: 10.3390/ijms25073722. Int J Mol Sci. 2024. PMID: 38612533 Free PMC article.
Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect.
Afonso J, Barbosa-Matos C, Silvestre R, Pereira-Vieira J, Gonçalves SM, Mendes-Alves C, Parpot P, Pinto J, Carapito Â, Guedes de Pinho P, Santos L, Longatto-Filho A, Baltazar F. Afonso J, et al. Among authors: santos l. Cancers (Basel). 2024 Apr 5;16(7):1418. doi: 10.3390/cancers16071418. Cancers (Basel). 2024. PMID: 38611096 Free PMC article.
Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.
Ferreira E, Ferreira D, Relvas-Santos M, Freitas R, Soares J, Azevedo R, Afonso LP, Lima L, Santos B, Gonçalves M, Silva AMN, Santos LL, Peixoto A, Ferreira JA. Ferreira E, et al. Among authors: santos ll. Int J Mol Sci. 2024 Mar 19;25(6):3462. doi: 10.3390/ijms25063462. Int J Mol Sci. 2024. PMID: 38542435 Free PMC article.
Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy.
Freitas R, Ferreira E, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Santos B, Gonçalves M, Quintas S, Peixoto A, Palmeira C, Silva AMN, Santos LL, Oliveira MJ, Sarmento B, Ferreira JA. Freitas R, et al. Among authors: santos ll. ACS Nano. 2024 Apr 9;18(14):10088-10103. doi: 10.1021/acsnano.3c12487. Epub 2024 Mar 27. ACS Nano. 2024. PMID: 38535625
Defining benchmarks for total and distal gastrectomy: global multicentre analysis.
Schneider MA, Kim J, Berlth F, Sugita Y, Grimminger PP, Sano T, Rosati R, Baiocchi GL, Bencivenga M, De Manzoni G, Nunobe S, Yang HK, Gutschow CA; GastroBenchmark Consortium; GASTRODATA Consortium. Schneider MA, et al. Br J Surg. 2024 Jan 31;111(2):znad379. doi: 10.1093/bjs/znad379. Br J Surg. 2024. PMID: 38377359 Free PMC article. No abstract available.
A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy.
Freitas R, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Ferreira E, Gaiteiro C, Soares J, Cotton S, Gonçalves M, Eiras M, Santos B, Palmeira C, Correia MP, Oliveira MJ, Sarmento B, Peixoto A, Santos LL, Silva AMN, Ferreira JA. Freitas R, et al. Among authors: santos ll. J Control Release. 2024 Mar;367:540-556. doi: 10.1016/j.jconrel.2024.01.065. Epub 2024 Feb 3. J Control Release. 2024. PMID: 38301927
160 results